MPG.eBooks - Description: CADTH Canadian Drug Expert Committee recommendation: Sodium zirconium cyclosilicate (Lokelma -- Astrazeneca Canada Inc.)

Cover Image

Read Now

CADTH Canadian Drug Expert Committee recommendation: Sodium zirconium cyclosilicate (Lokelma -- Astrazeneca Canada Inc.) indication: hyperkalemia

The CADTH Canadian Drug Expert Committee (CDEC) recommends that sodium zirconium cyclosilicate should not be reimbursed for the treatment of hyperkalemia in adults

Bibliographic Details
Corporate Author:	CADTH Canadian Drug Expert Committee
Format:	eBook
Language:	English
Published:	Ottawa (ON) CADTH March 27, 2020, 2020
Edition:	Final
Series:	CADTH common drug review
Subjects:	Insurance, Health, Reimbursement Silicates / Economics Canada Hyperkalemia / Drug Therapy Cost-benefit Analysis Silicates / Therapeutic Use
Online Access:	http://www.ncbi.nlm.nih.gov/books/NBK563695
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The CADTH Canadian Drug Expert Committee (CDEC) recommends that sodium zirconium cyclosilicate should not be reimbursed for the treatment of hyperkalemia in adults
Physical Description:	1 PDF file (10 pages)